Menu
Bluedot Bio believes that science is a collaborative venture and that the development of successful drugs benefits us all. For this reason, Bluedot prides itself on investing in biotechnology companies that aim to use novel approaches to combat disease. Bluedot selects its portfolio companies after a thorough screening process to ensure that scientific excellence is supported by a dedicated team. Currently, Bluedot’s portfolio companies each have the potential of changing the cancer treatment landscape by reinventing how we design, target, and deliver cancer drugs.
Attacking cancer using engineered immune cells (e.g. Chimeric Antigen Receptor T-cells; CAR-Ts) has transformed outcomes for patients with some types of blood cancer (e.g. B-cell lymphomas and acute lymphoblastic leukemias); however, this approach has failed to gain traction in solid tumors for two reasons ─ too much toxicity and not enough activity.
Chimera has innovated a suite of native T-cell inspired genetic engineering technologies to address the challenges in the field. Chimera’s differentiated RNA based technologies enable conditional, real-time control over CAR-T solving the critical challenges of safety and potency while extending persistence and efficacy. Chimera’s GOLD PLATFORM™ precisely controls gene expression in any cell therapy for greater efficacy against solid tumors and superior safety.
Rasio harnesses the power of next generation computer aided drug design to bring novel target development from discovery to delivery. Rasio designs molecules to optimally inhibit the functions of specific proteins by using its own computational software for cancer and other diseases.
Their mission addresses unmet patient needs through modeling of novel/deep cell binding regions. Rasio designs molecules to fit those regions and enhance treatment for cancer and other diseases. They work with the best researchers – and use the best computational chemistry software – to create effective therapies that only Rasio can develop.
Stromatis Pharma is paving the way to new therapeutic technologies that will treat many cancers. Founded in 2016, the company already has a portfolio of five novel high affinity antibodies that are protected under Intellectual Property. Their lead product is a monoclonal antibody called CT109 that targets a highly expressed protein in pancreatic and colorectal cancer. CT109 holds promise as a novel therapy in colorectal and pancreatic cancers, either as a stand-alone treatment or in combination with other drugs, therapies, and CT109-based Antibody Drug Conjugates (ADCs).
With a focus on developing antibodies to unique and unmet targets, Stromatis Pharma has licensed the rights to the DIAAD platform technology that generates new proprietary high affinity antibodies. They have been developing several proprietary antibodies to treat different cancer types.
